Shift From Adalimumab Originator to Biosimilars in Denmark

被引：58
|
作者：
Jensen, Thomas Bo [1 ]
Kim, Seoyoung C. [2 ]
Jimenez-Solem, Espen [1 ]
Bartels, Dorthe [3 ]
Christensen, Hanne Rolighed [1 ]
Andersen, Jon Traerup [1 ]
机构：
[1] Copenhagen Univ Hosp Bispebjerg, Dept Clin Pharmacol, Bispebjerg Bakke 23,Entrance 20C,2nd Floor, DK-2400 Copenhagen NV, Denmark
[2] Brigham & Womens Hosp, Div Pharmacoepidemiol & Pharmacoecon, 75 Francis St, Boston, MA 02115 USA
[3] Amgros, Copenhagen, Denmark
来源：
JAMA INTERNAL MEDICINE | 2020年 / 180卷 / 06期
关键词：
D O I：
10.1001/jamainternmed.2020.0338
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：902 / 903
页数：2
相关论文
共 50 条
  • [41] A Survey Among IBD Patients Following Switching From Originator Infliximab to Its Biosimilars
    Doan, Anh Trinh
    Johnson, Christopher
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2024, 119 (10S): : S867 - S867
  • [42] EFFICACY AND DRUG SURVIVAL AFTER MULTIPLE-SWITCHING FROM ADALIMUMAB ORIGINATOR TO THE BIOSIMILARS ABP501 AND SB5: A REAL-LIFE STUDY
    Parisi, S.
    Becciolini, A.
    Ditto, M. C.
    Ariani, A.
    Ianniello, A.
    Priora, M.
    Paroli, M.
    Realmuto, C.
    Peroni, C. L.
    Di Vittorio, C. M. Centanaro
    Degiovanni, R.
    Lagana, A.
    Fusaro, E.
    ANNALS OF THE RHEUMATIC DISEASES, 2022, 81 : 1295 - 1296
  • [43] Switching from Adalimumab Originator to Biosimilar: Clinical Experience in Patients with Hidradenitis Suppurativa
    Montero-Vilchez, Trinidad
    Cuenca-Barrales, Carlos
    Rodriguez-Tejero, Andrea
    Martinez-Lopez, Antonio
    Arias-Santiago, Salvador
    Molina-Leyva, Alejandro
    JOURNAL OF CLINICAL MEDICINE, 2022, 11 (04)
  • [44] Switching from adalimumab originator to biosimilar: clinical experience in hidradenitis suppurativa patients
    Montero-Vilchez, Trinidad
    Rodriguez-Tejero, Andrea
    Sanchez-Diaz, Manuel
    Arias-Santiago, Salvador
    Molina-Leyva, Alejandro
    EXPERIMENTAL DERMATOLOGY, 2021, 30 : 80 - 80
  • [45] Increased monitoring of biologicals and biosimilars in Denmark
    Reactions Weekly, 2016, 1594 (1) : 2 - 2
  • [46] Shift work - The view from Denmark
    Erichsen, Shariha Khalid
    BMJ-BRITISH MEDICAL JOURNAL, 2007, 334 (7599): : 864 - 864
  • [47] AN AUDIT OF ORIGINATOR ADALIMUMAB TO BIOSIMILAR SWITCH IN TWO HOSPITALS
    Mazumder, R.
    Loke, M.
    Mukhtyar, C.
    Gaffney, K.
    Balogh, E.
    Sekaran, E.
    Sultana, M.
    Odonkor, M.
    Miles, K.
    ANNALS OF THE RHEUMATIC DISEASES, 2020, 79 : 1876 - 1876
  • [48] Adalimumab Biosimilars in Europe: An Overview of the Clinical Evidence
    Salvatore Bellinvia
    J. R. Fraser Cummings
    Michael R. Ardern-Jones
    Christopher J. Edwards
    BioDrugs, 2019, 33 : 241 - 253
  • [49] Adalimumab Biosimilars in Europe: An Overview of the Clinical Evidence
    Bellinvia, Salvatore
    Cummings, J. R. Fraser
    Ardern-Jones, Michael R.
    Edwards, Christopher J.
    BIODRUGS, 2019, 33 (03) : 241 - 253
  • [50] Real-world experience and long-term outcomes of a mandatory non-medical switch of adalimumab originator to biosimilars in inflammatory bowel disease
    Kiow, Jeremy Liu Chen
    Hoang, Thomas
    Bedi, Harjot K.
    Ardekani, Zhina Majdzadeh
    Rosenfeld, Daniel
    Reise-Filteau, Marica
    Bressler, Brian
    Leung, Yvette
    Rosenfeld, Greg
    WORLD JOURNAL OF GASTROENTEROLOGY, 2024, 30 (46)
12345